Deborah M. Stephens, DO, of The University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, summarizes the treatments available for young and fit patients with newly diagnosed chronic lymphocytic leukemia (CLL). Dr Stephens discusses the treatment of patients with low-risk CLL, such as those with mutated IGHV and/or del(13q), and highlights the benefits of chemoimmunotherapy, such as fludarabine, cytarabine and rituximab, also commenting on the associated risks. Dr Stephens also talks on the use of ibrutinib in the frontline setting for this patient subgroup, as well as second-generation BTK inhibitors such as acalabrutinib. Finally, Dr Stephens outlines the use of venetoclax plus obinutuzumab as a fixed-duration treatment approach which may be suitable for low-risk newly-diagnosed patients with CLL. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.